Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. The announcement of a peer-reviewed paper entitled “Chemoablation of metastatic melanoma using intralesional Rose Bengal,” which can be found on the Provectus website, will soon be published in the December issue of “Melanoma Research.”
Our Director of Marketing had the great fortune to see Provectus Pharmaceuticals up close and in person during a recent conference and sat aghast as they unveiled cancer after cancer being treated and then cured by their PV-10 drug. If you have a moment to take a look at the clinical photos of the melanoma research, we highly recommend it. The paper presents the clinical data for the first 11 subjects in Phase 1 trial.
According to the paper, twenty-six target lesions were injected with PV-10, and an additional 28 lesions were observed without treatment to assess the bystander effect. The bystander effect of PV-10 was incredible, curing 90% of the remaining melanomas.
The authors note, “The treatment was well tolerated and an objective response was observed in 12 target lesions, with an additional seven lesions remaining static over at least 12 weeks of observation. In this dose-evaluation study, response rate was dose dependent, increasing to 69% after higher dose injections. Nontarget lesions exhibited a 27% objective response rate that increased to 44% in patients exhibiting a positive response of target lesions. These findings indicate that intralesional Rose Bengal is nontoxic and could benefit patients with metastatic melanoma.”
Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs; PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. The Company has received orphan drug designation from the FDA for its melanoma indication, which in essence, fast-tracks the drug through the FDA.
Let us hear your thoughts below: